Popular weight-loss drug Wegovy maker Novo Nordisk expects high demand and acceptance for its anti-obesity drug, when ...

Third quarter sales of Novo’s in-demand obesity drug totaled $2.5 billion, roughly 81% higher than the same period in 2023 ...

Shares in Novo Nordisk which competes with Eli Lilly in an obesity drug market that some analysts forecast could be worth about $150 billion by the early 2030s, rose nearly 9%.

We recently compiled a list of the 10 Best Reddit Stocks To Buy Right Now. In this article, we are going to take a look at where Eli Lilly And Co.

Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...

With a gain of more than 531% over the last 12 months, shares of Viking Therapeutics (NASDAQ: VKTX) are a hot commodity, to ...

Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...

Also Read: Eli Lilly Sues Some Vendors For Unauthorized Sale Of Fake Weight-Loss Drug However, he noted that no definitive ..

Lexaria's strategy is to continue developing and optimizing our wholly-owned DehydraTECH™ drug delivery platform for application in the GLP-1 space, positioning it as a 'must-have' technology for ...

Novo Nordisk's third-quarter sales for Wegovy exceeded expectations, relieving investors concerned about demand slowdown.

Redwire Corporation (NYSE: RDW), a leader in space infrastructure for the next generation space economy, announced today that its third batch of pharm ...

Wave Life Sciences is planning to extend its RNA editing technology to treat Huntington’s disease, Duchenne muscular ...